Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Three DKFZ researchers elected as new EMBO members

No. 43a | 07/07/2020 | by Thiel

Ursula Klingmüller, Ana Martin-Villalba, and Aurelio Teleman have been admitted to the European Molecular Biology Organization (EMBO) for their outstanding research. EMBO is an organization of more than 1,800 researchers deemed to be among the best in the world in their areas of research.

Membership of EMBO is regarded as a recognition of scientific excellence throughout the world. Every year, the organization adds new researchers to its network after they have been nominated and selected by existing members for their outstanding research in the field of life sciences. Members can play an active role in shaping the organization's work as a member of the Council, by evaluating funding applications, or as a mentor to junior scientists. In this year's selection process, EMBO announced three researchers from the German Cancer Research Center (DKFZ) as new members.

Ursula Klingmüller
© DKFZ/Jung

Systems biologist Ursula Klingmüller has been conducting research at the DKFZ since 2003. She uses mathematical models and time-resolved data to examine cellular networks that determine the fate of a cell – survival, division, differentiation, or death. Klingmüller studied biology at the universities of Bayreuth and Heidelberg and earned her doctorate at the Center for Molecular Biology in Heidelberg (ZMBH). She has been a member of the German Ethics Council since 2016.

Ana Martin-Villalba
© DKFZ/Jung

Ana Martin-Villalba studies the degenerative processes in the central nervous system in old age and in diseases, comparing them with regeneration after damage to the pancreatic gland, among other things. She focuses on the regeneration potential of stem cells and their role in carcinogenesis. Ana Martin-Villalba studied medicine at the University of Murcia in Spain and in Leeds, UK before obtaining a doctorate from the University of Heidelberg. She has already received the Paul Ehrlich and Ludwig Darmstaedter Award and the Heinz Maier-Leibnitz Prize.

Aurelio Teleman
© DKFZ/Schwerdt

Aurelio Teleman studied biochemistry at Harvard University before completing a doctorate at Imperial College London and at the European Molecular Biology Laboratory (EMBL) in Heidelberg. He has been investigating the regulation of cell growth at the DKFZ since 2007. His achievements include the discovery of a new and surprising signaling pathway: He established that stearic acid, a fatty acid, is not only a metabolic product, but also steers important biochemical processes in the cell. In addition to other honors and awards, Teleman was awarded the EMBO Young Investigator Award back in 2010.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Cancer Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS